Vivo Capital, LLC Unicycive Therapeutics, Inc. Transaction History
Vivo Capital, LLC
- $512 Million
- Q4 2024
A detailed history of Vivo Capital, LLC transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Vivo Capital, LLC holds 9,970,152 shares of UNCY stock, worth $6.18 Million. This represents 1.54% of its overall portfolio holdings.
Number of Shares
9,970,152
Previous 4,470,152
123.04%
Holding current value
$6.18 Million
Previous $1.83 Million
329.91%
% of portfolio
1.54%
Previous 0.27%
Shares
3 transactions
Others Institutions Holding UNCY
# of Institutions
32Shares Held
61.7MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT11MShares$6.81 Million5.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT10.4MShares$6.44 Million0.41% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$6.2 Million1.76% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3.15 Million0.53% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$3.1 Million0.01% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $9.33M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...